Catalyst Event

Bristol-Myers Squibb Co (BMY) · Other

From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)

6/11/2026, 12:00:00 AM

OtherSentiment: Negative

Takeda announced its experimental drug zasocitinib was superior to BMY's Sotyktu in a Phase 3 trial for treating moderate-to-severe plaque psoriasis. Takeda plans to seek regulatory approval in its 2026 fiscal year.

Korean Translation

다케다가 중등도-중증 판상 건선 치료를 위한 3상 임상시험에서 자사의 실험약 자소시티닙이 BMY의 소틱투보다 우월했다고 발표함. 다케다는 2026 회계연도에 규제 승인을 모색할 계획임.

Related Recent Events

View Full Timeline